Francesco Marampon

Rome, 00161, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 161 publications

Revisiting the Abscopal Effect in the Era of Immuno-Radiotherapy: Mechanisms, Challenges, and Clinical Perspectives.

Revisiting the Abscopal Effect in the Era of Immuno-Radiotherapy: Mechanisms, Challenges, and Clinical Perspectives.

Journal: Biomolecules

Published: July 02, 2026

Catalase Defines Radiotherapy Resistance and a Therapeutic Vulnerability in Rhabdomyosarcoma.

Catalase Defines Radiotherapy Resistance and a Therapeutic Vulnerability in Rhabdomyosarcoma.

Journal: International journal of molecular sciences

Published: June 01, 2026

Tumor Treating Fields and the Glioblastoma Microenvironment: Mechanistic Convergences with Radiotherapy.

Tumor Treating Fields and the Glioblastoma Microenvironment: Mechanistic Convergences with Radiotherapy.

Journal: Cancers

Published: May 28, 2026

Integrative Meta-Analysis Identifies Epithelial-Mesenchymal Transition Gene Signatures as Key Determinants of Ovarian Cancer Progression and Treatment Outcome.

Integrative Meta-Analysis Identifies Epithelial-Mesenchymal Transition Gene Signatures as Key Determinants of Ovarian Cancer Progression and Treatment Outcome.

Journal: International journal of molecular sciences

Published: January 12, 2026

From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment.

From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment.

Journal: Frontiers in cell and developmental biology

Published: December 23, 2025

RETRACTED: Gravina et al. The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models. Cancers 2019, 11, 359.

RETRACTED: Gravina et al. The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models. Cancers 2019, 11, 359.

Journal: Cancers

Published: December 23, 2025

RETRACTED: Gravina et al. The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models. Cancers 2019, 11, 1604.

RETRACTED: Gravina et al. The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models. Cancers 2019, 11, 1604.

Journal: Cancers

Published: December 23, 2025

Clinical outcomes of three-fraction versus five-fraction stereotactic radiosurgery for resected brain metastases.

Clinical outcomes of three-fraction versus five-fraction stereotactic radiosurgery for resected brain metastases.

Journal: Journal of neuro-oncology

Published: October 12, 2025

Timing matters: overall treatment time, radiotherapy interruptions, and outcomes in glioblastomas-prognostic significance in different biological sub-groups.

Timing matters: overall treatment time, radiotherapy interruptions, and outcomes in glioblastomas-prognostic significance in different biological sub-groups.

Journal: Journal of neuro-oncology

Published: July 18, 2025

Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma.

Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: July 16, 2025

Multi-omics analyses identify EZH2 as a central driver in rhabdomyosarcoma radioresistance and highlight Tazemetostat as an effective radiosensitizer in vitro and in vivo.

Multi-omics analyses identify EZH2 as a central driver in rhabdomyosarcoma radioresistance and highlight Tazemetostat as an effective radiosensitizer in vitro and in vivo.

Journal: Cell death & disease

Published: July 11, 2025

The HIV Protease Inhibitor Ritonavir Reverts the Mesenchymal Phenotype Induced by Inflammatory Cytokines in Normal and Tumor Oral Keratinocytes to an Epithelial One, Increasing the Radiosensitivity of Tumor Oral Keratinocytes.

The HIV Protease Inhibitor Ritonavir Reverts the Mesenchymal Phenotype Induced by Inflammatory Cytokines in Normal and Tumor Oral Keratinocytes to an Epithelial One, Increasing the Radiosensitivity of Tumor Oral Keratinocytes.

Journal: Cancers

Published: June 24, 2025

Showing 1-12 of 161

Last Updated: 09/26/2026